Thanks for posting that useful FDA information, xeno9. While...

Thanks for posting that useful FDA information, xeno9.

While there is a strong case for NAN and PO3 to present their disinfection technologies to the FDA, it seems that both groups are very busy preparing for new product launches.

In NAN's case, management is working on disinfection of medical surfaces and instruments such as endoscopes.

In PO3's case, management is also working on disinfection for surfaces and medical instruments such as endoscopes and ultrasound probes.

PO3 evidently believes that if NAN's hydrogen peroxide tech can effectively cleanse probes then PO3's FRG/free radical generator tech can do the job at least as well.

In this context, I note that PO3's 2019 annual report published on Monday this week includes a table which purports to show that FRG hydroxyl radicals can outperform hydrogen peroxide by some 57%.

Further demonstrating that PO3 is tracking NAN is the decision by PO3 executive director Simon Lill on August 27 to advise the ASX that a rise in PO3's share price paralleled a rise in the NAN share price.

As you say, it will be interesting to see "whether PO3 (and/or NAN) participate in the FDA submission process, or whether they are happy keep their focus respectively on more immediate business priorities."